Development of MK-4827: A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors

被引：0

作者：

Jones, Philip ^{[1
]}

Altamura, Sergio ^{[1
]}

Boueres, Julia ^{[1
]}

Ferrigno, Federica ^{[1
]}

Fonsi, Massimiliano ^{[1
]}

Gavory, Gerald ^{[1
]}

Giomini, Claudia ^{[1
]}

Koch, Uwe ^{[1
]}

Lamartina, Stefania ^{[1
]}

Monteagudo, Edith ^{[1
]}

Ontoria, Jesus M. ^{[1
]}

Roscilli, Giuseppe ^{[1
]}

Rowley, Michael ^{[1
]}

Scarpelli, Rita ^{[1
]}

Schultz-Fademrecht, Carsten ^{[1
]}

Toniatti, Carlo ^{[1
]}

机构：

[1] IRBM Merck Res Labs Rome, I-00040 Pomezia, Italy

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

220-MEDI

引用

页数：1

共 50 条

[11] First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
Wenham, R. M.
Sandhu, S. K.
Wilding, G.
Sun, L.
Toniatti, C.
Stroh, M.
Carpenter, C.
de-Bono, J.
Baird, R.
Schelman, W. R.
EJC SUPPLEMENTS, 2010, 8 (07): : 114 - 115
[12] Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
Sandhu, S. K.
Wilding, G.
Schelman, W. R.
Omlin, A.
Kreischer, N.
Carpenter, C.
Iannone, R.
Kaye, S.
de-Bono, J. S.
Wenham, R. M.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 107 - 108
[13] Modulatory Potential of Poly (ADP-Ribose) Polymerase 1 (PARP1) in BRCA-Mutated Tumors
Munyembaraga, Valens
Cyuzuzo, Delphine
Dao, Tran Nhat Phong
Oyinloye, Babatunji Emmanuel
Onikanni, Sunday Amos
Chang, Hen-Hong
EUROPEAN JOURNAL OF CANCER CARE, 2024, 2024
[14] Testing of a poly(ADP-ribose) polymerase ( PARP) inhibitor on human BRCA2 heterozygous cell lines
Halldorsdottir, A. M.
Vidarsdottir, L.
Stefansson, O. A.
Bjarnason, H.
Bodvarsdottir, S. K.
Eyfjord, J. E.
EJC SUPPLEMENTS, 2010, 8 (05): : 57 - 57
[15] First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
Wenham, R.
Wilding, G.
Baird, R.
Sun, L.
Toniatti, C.
Stroh, M.
Carpenter, C.
de-Bono, J.
Sandhu, S.
Schelman, W.
GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S5 - S6
[16] Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Jones, Philip
Wilcoxen, Keith
Rowley, Michael
Toniatti, Carlo
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) : 3302 - 3314
[17] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Sandhu, Shahneen K.
Schelman, William R.
Wilding, George
Moreno, Victor
Baird, Richard D.
Miranda, Susana
Hylands, Lucy
Riisnaes, Ruth
Forster, Martin
Omlin, Aurelius
Kreischer, Nathan
Thway, Khin
Gevensleben, Heidrun
Sun, Linda
Loughney, John
Chatterjee, Manash
Toniatti, Carlo
Carpenter, Christopher L.
Iannone, Robert
Kaye, Stan B.
de Bono, Johann S.
Wenham, Robert M.
LANCET ONCOLOGY, 2013, 14 (09): : 882 - 892
[18] Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu, S. K.
Omlin, A.
Hylands, L.
Miranda, S.
Barber, L. J.
Riisnaes, R.
Reid, A. H.
Attard, G.
Chen, L.
Kozarewa, I.
Gevensleben, H.
Campbell, J.
Fenwick, K.
Assiotis, I.
Olmos, D.
Yap, T. A.
Fong, P.
Tunariu, N.
Koh, D.
Molife, L. R.
Kaye, S.
Lord, C. J.
Ashworth, A.
de Bono, J.
ANNALS OF ONCOLOGY, 2013, 24 (05) : 1416 - 1418
[19] Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and-2 inhibitor
Zhang, Z-Y.
Wang, X.
Wang, J.
Pentikis, H. S.
Kansra, V.
ANNALS OF ONCOLOGY, 2017, 28
[20] Iniparib. Poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, Oncolytic
Li, J.
Glencer, A.
Rugo, H. S.
DRUGS OF THE FUTURE, 2012, 37 (11) : 777 - 786

← 1 2 3 4 5 →